HAS3 and ovarian serous adenocarcinoma: We additionally showed that expression of HAS2 and HAS3 but not HAS1 or hyaluronidases HYAL1 and HYAL2 were significantly increased in chemoresistant compared to chemosensitive primary serous ovarian cancer cells.